- Home »
- Market Insights »
- Upcoming Biotech Phase 3 Trial Readouts (June 2026)
Upcoming Biotech Phase 3 Trial Readouts (June 2026)
A calendar of upcoming biotech Phase 3 trial readouts tracked by MarketsHost from public regulatory and clinical-trial sources. Informational only.
by Mubarak
Published Jun 14, 2026 | Updated Aug 03, 2026 | 📖 3 min read
Article continues below advertisement
This calendar tracks upcoming Phase 3 clinical trial readouts for biotechnology companies, organized by expected announcement date. Each entry pairs a company and ticker symbol with a specific drug candidate or development program. Dates are sourced from public regulatory filings and clinical trial registries, though timelines may shift as development progresses.
Phase 3 trial outcomes represent critical inflection points for biotech firms and investors alike. These readouts influence market perception, inform regulatory pathways, and chart the course of clinical development. For those following the sector, monitoring these milestones offers crucial visibility into the pipeline progress of major biotech players and signals within the broader innovation space.
Upcoming Biotech Phase 3 Readouts
| # | Date | Company | Ticker | Drug / Trial |
|---|---|---|---|---|
| 1 | Aug 3, 2026 | Option Therapeutics Inc. | OPTN | A Study to Provide Continued Access to and Assess Long-Term Safety of the Stu… |
| 2 | Aug 8, 2026 | Sanofi | SNY | A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatri… |
| 3 | Aug 10, 2026 | INCYTE CORP | INCY | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric… |
| 4 | Aug 14, 2026 | IQVIA HOLDINGS INC. | IQV | Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 … |
| 5 | Aug 24, 2026 | Inhibitor Therapeutics, Inc. | INTI | A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Co… |
| 6 | Aug 28, 2026 | Glucose Health, Inc. | GLUC | The Fenofibrate And Microvascular Events in Type 1 Diabetes Eye. |
| 7 | Aug 31, 2026 | Atrium Therapeutics, Inc. | RNA | Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negat… |
| 8 | Aug 31, 2026 | Atrium Therapeutics, Inc. | RNA | Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients… |
| 9 | Aug 31, 2026 | Atrium Therapeutics, Inc. | RNA | Additional Support Program Via Text Messaging and Telephone-Based Counseling … |
| 10 | Aug 31, 2026 | Inhibitor Therapeutics, Inc. | INTI | Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG |
| 11 | Aug 31, 2026 | Inhibitor Therapeutics, Inc. | INTI | A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Part… |
| 12 | Sep 1, 2026 | ARGENX SE | ARGX | A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adu… |
| 13 | Sep 1, 2026 | SUPERNUS PHARMACEUTICALS, INC. | SUPN | Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxa… |
| 14 | Sep 1, 2026 | Disc Medicine, Inc. | IRON | Study of Bitopertin in Participants With EPP or XLP (APOLLO) |
| 15 | Sep 1, 2026 | ARDELYX, INC. | ARDX | Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pe… |
| 16 | Sep 1, 2026 | Atea Pharmaceuticals, Inc. | AVIR | C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic… |
| 17 | Sep 1, 2026 | REGENXBIO Inc. | RGNX | AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscula… |
| 18 | Sep 1, 2026 | NEUTRA CORP. | NTRR | Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis |
| 19 | Sep 1, 2026 | Alkermes plc. | ALKS | Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatr… |
| 20 | Sep 1, 2026 | INCYTE CORP | INCY | Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-int… |
How this list is compiled
Events are sourced from public US-government and clinical-trial data (SEC filings, the Federal Register and ClinicalTrials.gov) and ordered by date. Dates can change; always confirm with primary sources. Figures are pulled automatically from MarketsHost data and refreshed regularly. This page is for general information only and is not investment, financial or trading advice.
For the underlying data, explore the BioPharma FDA catalyst tracker on MarketsHost.
Related Articles
Frequently Asked Questions
. What is a Phase 3 readout?
A Phase 3 readout is the release of results from a large, late-stage clinical trial — a key milestone in a drug's path to potential approval.
. Are these dates guaranteed?
No. Regulatory and trial timelines can move. The calendar reflects the most recent public estimates and should be confirmed against primary sources.
Disclaimer : The above information is for general informational purposes only. All information on the Site is provided in good faith, however we make no representation or warranty of any kind, express or implied, regarding the accuracy, adequacy, validity, reliability, availability or completeness of any information on the Site.